Skip to main content
Contact Us
Subscribe
E-Edition
82°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
13.77
+0.10 (+0.73%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
More Than 140 Drug Brands Will Have Their Prices Hiked Heading Into 2024
January 04, 2024
More than 140 brands of drugs are going to see their prices hiked heading into the new year
Via
Talk Markets
Expensive Drugs For Americans In 2024? Drugmakers Including Pfizer, Sanofi Mull Price Increase In January
December 29, 2023
Just as large pharma companies prepare a showdown with Medicare's newfound power to negotiate down drug prices, several major drug companies are reportedly gearing up to implement price increases on...
Via
Benzinga
(TAK) - Analyzing Takeda Pharmaceutical's Short Interest
December 25, 2023
Via
Benzinga
One Ultra-Cheap High-Yield Dividend Stock to Buy
December 22, 2023
Now may be a good time for dividend investors to consider loading up on this stock.
Via
The Motley Fool
Ionis' Strategic Shift Praised by Analysts For Donidalorsen's Global Reach
December 19, 2023
Monday, Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered into a license agreement with Otsuka Pharmaceutical Co Ltd under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen,...
Via
Benzinga
(TAK) - Analyzing Takeda Pharmaceutical's Short Interest
December 07, 2023
Via
Benzinga
Peering Into Takeda Pharmaceutical's Recent Short Interest
November 21, 2023
Via
Benzinga
Looking Into Takeda Pharmaceutical's Recent Short Interest
November 03, 2023
Via
Benzinga
A Look Into Takeda Pharmaceutical Inc's Price Over Earnings
October 19, 2023
Via
Benzinga
Why Is Neurocrine Biosciences Stock Trading Lower Today?
November 10, 2023
Thursday, Neurocrine Biosciences Inc (NASDAQ: NBIX)
Via
Benzinga
Back To Back FDA Approval For Takeda Within Two Days, Secures Green Signal For Rare Blood Disorder Therapy
November 10, 2023
The FDA approved Takeda Pharmaceutical Co Ltd's (NYSE:
Via
Benzinga
Exposures
Product Safety
3 Promising Biotech Stocks Flying Under the Radar
November 08, 2023
Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.
Via
InvestorPlace
Alkermes Plummets In Huge Volume. Why One Analyst Says The Reaction Is Overdone.
October 23, 2023
Analysts say Alkermes' drug is clearly active. But investors have concerns.
Via
Investor's Business Daily
Week In Review: China's Biopharmas Announce $2.5 Billion In Deals
October 21, 2023
KBP Biosciences sold global rights for its hypertension candidate to Novo Nordisk in an agreement worth up to $1.3 billion. Also, EpimAb Bio sold the rights to use its Fabs-In-Tandem Immunoglobulin...
Via
Talk Markets
Looking Into Takeda Pharmaceutical's Recent Short Interest
October 11, 2023
Via
Benzinga
A Look Into Takeda Pharmaceutical Inc's Price Over Earnings
October 04, 2023
Via
Benzinga
Looking Into Takeda Pharmaceutical's Recent Short Interest
September 25, 2023
Via
Benzinga
(TAK) - Analyzing Takeda Pharmaceutical's Short Interest
September 08, 2023
Via
Benzinga
Earnings Scheduled For October 26, 2023
October 26, 2023
Companies Reporting Before The Bell • TotalEnergies (NYSE:TTE) is likely to report quarterly earnings at $2.57 per share on revenue of $49.83 billion.
Via
Benzinga
Takeda's Crohn's Disease Fistulas Candidates Fall Short In Mid-Stage Study, Settles Tax Dispute With Irish Revenue Commissioners
October 18, 2023
Takeda Pharmaceutical Co Ltd (NYSE: TAK) released topline data from the Phase 3 ADMIRE-CD II study, assessing Alofisel (darvadstrocel) for complex Crohn's Perianal Fistulas (CPF).
Via
Benzinga
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories
October 03, 2023
Benzinga
Via
Benzinga
Takeda Withdraws Lung Cancer Drug From US After Failed Confirmatory Trial
October 03, 2023
Following discussions with the FDA, Takeda Pharmaceutical Co Ltd (NYSE: TAK) will voluntarily withdraw Exkivity (mobocertinib)
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
October 02, 2023
Via
Benzinga
Can Japan's Economy Continue To Blossom If Bank of Japan Raises Rates? Apparently So.
October 02, 2023
Amid an economic climate of high interest rates in the US and a slumber among China stocks led by a downturn in the property market, Japan’s economy lies in stark contrast to the antipathy that...
Via
Benzinga
Topics
Economy
Exposures
Economy
Morphic Therapeutic's Stock Plunges On Monday - Here's Why?
September 25, 2023
Since Friday, Morphic Therapeutic (NASDAQ: MORF) shares have plunged from $47.92 to $26.25 after the company announced the publication of an abstract discussing new EMERALD-1 phase 2a primary results...
Via
Benzinga
The Surprise That Prompted Morphic Therapeutic To Dump 52% Over Two Days
September 25, 2023
The company is working on a treatment for ulcerative colitis. But competitive questions linger.
Via
Investor's Business Daily
Top 4 Health Care Stocks That Should Keep You Up At Night
September 21, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
Is This 250-Year-Old Japanese Big Pharma Giant Selling For Half Price Right Now?
September 18, 2023
When it comes to Big Pharma, Japan’s Takeda Pharmaceutical Co Ltd (NYSE: TAK) is a conservative play that could prove to be a big winner given its cheap valuation and suite of new drugs that portend to...
Via
Benzinga
Ovarian Cancer Player ImmunoGen Can Potentially Be Attractive M&A Target: JP Morgan
September 13, 2023
JP Morgan upgraded ImmunoGen Inc (NASDAQ: IMGN) from Neutral to Overweight with a price target of $22, up from $9, based on insights gathered from a recent physician survey, which focused on the...
Via
Benzinga
ImmunoGen Inks Pact With Takeda To Develop ELAHERE Ovarian Cancer Drug In Japan
August 28, 2023
ImmunoGen, Inc. (NASDAQ: IMGN) inked pacts with Takeda Pharmaceutical Company Limited (NYSE: TAK) to develop and
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.